NEW! Subscribe to Medtech Pro and get one or all of our reports, plus much more.

March Emerging Medical Technologies Report

17 Pages | 30 Exhibits |
market-report-samples/GlobalMarketSegments2.jpg market-report-samples/GlobalMarketSegments3caps.jpg market-report-samples/GlobalMarketSegmentsCaps.jpg
Buy Now

Overview

This report includes details on 30 emerging medical technology companies that have been identified by LSI's in-house research team in March 2013.

All companies include technology, market(s), key executive, and contact information.

Coverage includes innovations in a broad spectrum of medical technology areas including:
- Aesthetics/Dermatology Companies
- Biomaterials Companies
- Biotechnology/Cell Therapy Companies
- Cardiovascular Companies
- Dental Companies
- Diagnostics Companies
- Drug Delivery Companies
- Endocrine Companies
- Gastroenterology Companies
- Gynecology/Women's Health Companies
- Imaging Companies
- Neurology Companies
- Oncology Companies
- Ophthalmology Companies
- Orthopedics Companies
- Pain Management Companies
- Patient Management/Monitoring Companies
- Pharmaceutical Companies
- Respiratory Companies
- Spine Companies
- Surgery Companies
- Urology Companies
- Vascular Companies
- Wound Management Companies

This report is included in LSI's Emerging Medical Technologies® Database.

Table of Contents

BRIEF TECHNOLOGY DESCRIPTIONS FOR COMPANIES COVERED


•1-Prescription-only nutraceutical for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease (AD), 2-A drug for the treatment of Parkinson's disease (PD), and 3-A drug that addresses mitochondrial dysfunction in Huntington's disease (HD)
In vitro diagnostics platform for medically important gene signatures, including a new application for intrinsic subtyping of breast cancer
•Advanced wound care dressings with a unique cross-linked polymer composition that can first store, then release, water or other aqueous-based materials - at controllable rates
•Cloud-based SAAS solution for comprehensive remote physiological monitoring with a focus on arrhythmia detection
•Deuterium-substituted compounds that can be developed more quickly and less expensively than conventional new chemical entities (NCEs), and with less risk
•Disease-modifying replacement peptide for the treatment of complications associated with diabetes
•Drug discovery platform that provides an atomic-level, three-dimensional (3-D) understanding of interactions between drug candidates and their bacterial targets to enable the design of antibiotics with enhanced characteristics
•Entirely disposable, battery-powered sample preparation devices that efficiently lyse any cell type and simultaneously extract DNA or RNA
•MicroRNA-based therapeutics for cancer
•Minimally invasive, catheter-based approach focused on Carotid Body Modulation(TM) (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes, and renal failure
•Minimally-invasive implant for the treatment of hand osteoarthritis, as an early-stage alternative to chronic drug therapies and irreversible joint replacement surgery
•Monoclonal antibody for the treatment of chronic migraine that is capable of reducing both frequency and severity of migraines without debilitating side effects
•New, "purification free" approach to Human Leukocyte Antigen (HLA) typing that enables faster, easier-to-use, and significantly less costly genetic testing products
•Next-generation image-guidance device to: 1-Find small or deep tumors which cannot yet be easily spotted by ultrasound and 2-Allow needle-guided interventions to be done without the need for expensive, cumbersome external tracking devices that are currently used
•Next-generation, ultra-fast, and easy-to-use DNA testing device capable of "real-time" Polymerase Chain Reaction (PCR)
•Non-invasive highly-differentiated cortical stimulation technology to help treat and diagnose centralized chronic pain, such as fibromyalgia
•Non-surgical, fully-reversible device for weight loss
•Novel protein drug for the treatment of Graves' Orbitopathy (GO)
•Orthopedic joint implants and associated surgical instruments
•Platform that utilizes a blood-based proteomic assessment of disease-specific exosomes or microvesicles for a variety of prenatal and oncology conditions
•Redox-based drugs targeting rare- or orphan-inherited mitochondrial respiratory chain diseases that are highly debilitating, life-threatening, and have no FDA- or EMA-approved drugs available to treat them
•Reusable, modular sterilization tray system that saves surgical departments time and money, while reducing the potential risk of infection from contaminated instruments
•Revolutionary, next-generation bi-modal platform technology which fundamentally changes the utilization of conventional ultrasound both as a modality for diagnostic imaging and as an active screening method
•Robust and cost-effective multi-parameter patient monitoring technology that allows individuals, doctors, caregivers and family members to remotely and collaboratively manage a patient's health and wellness 24/7
•System for the transvaginal delivery of large and small molecule drugs, with an initial target in women's reproductive endocrinology disorders and follow-on applications in diabetes, obesity, and infectious disease
•System that can vacuum out kidney stones (smaller than 10mm) from a patient's urethra in just ten seconds, at the physician's office
•Technology to detect diabetic foot ulcers before they develop - an insole with sensors that gathers and wirelessly transmits continuous information about a patient's feet
•The first dental laser technology that delivers on the promise of hard and soft tissue ablation with speed and precision
•The only technology that has the sensitivity to: detect every gene in the human transcriptome in situ and simultaneously quantify multiple mRNA transcripts at a single cell level
•Women's health products for the prevention of Human Papillomavirus (HPV) and Sexually Transmitted Diseases (STDs)